About Dr. Reddy's Laboratories Limited
https://www.drreddys.comDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments.
CEO
Erez Israeli
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-05 | Forward | 5:1 |
| 2006-09-07 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 56
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V.
Shares:13.08M
Value:$174.02M
BLACKROCK, INC.
Shares:11.16M
Value:$148.43M
ROYAL BANK OF CANADA
Shares:10.16M
Value:$135.16M
Summary
Showing Top 3 of 306
About Dr. Reddy's Laboratories Limited
https://www.drreddys.comDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $88.05B ▲ | $30.63B ▼ | $14.37B ▲ | 16.32% ▼ | $17.27 ▲ | $24.31B ▼ |
| Q1-2026 | $85.45B ▲ | $31.15B ▲ | $14.18B ▼ | 16.59% ▼ | $17.04 ▼ | $24.64B ▼ |
| Q4-2025 | $85.06B ▲ | $29.62B ▼ | $15.94B ▲ | 18.74% ▲ | $19.13 ▲ | $25.26B ▲ |
| Q3-2025 | $83.59B ▲ | $30.33B ▲ | $14.13B ▲ | 16.91% ▲ | $16.96 ▲ | $24.28B ▲ |
| Q2-2025 | $80.16B | $30.22B | $12.55B | 15.66% | $15.06 | $23.9B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $69.81B ▲ | $542B ▲ | $179.92B ▲ | $358.49B ▲ |
| Q1-2026 | $66.69B ▲ | $519.54B ▲ | $165.78B ▲ | $350.06B ▲ |
| Q4-2025 | $57.91B ▼ | $492.99B ▲ | $155.82B ▼ | $333.39B ▲ |
| Q3-2025 | $59.18B ▼ | $481.06B ▲ | $159.49B ▲ | $317.72B ▲ |
| Q2-2025 | $63.07B | $465.95B | $156.67B | $305.34B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $14.27B ▲ | $15.57B ▲ | $-9.54B ▲ | $-5.32B ▼ | $902M ▲ | $5.44B ▲ |
| Q1-2026 | $14.1B ▼ | $14.63B ▼ | $-19.19B ▼ | $-1.2B ▲ | $-5.59B ▼ | $4.48B ▼ |
| Q4-2025 | $15.87B ▲ | $22B ▲ | $-13.3B ▼ | $-7.37B ▼ | $1.56B ▼ | $10.75B ▲ |
| Q3-2025 | $14.04B ▲ | $6.62B ▼ | $-5.46B ▲ | $590M ▼ | $1.75B ▼ | $-2.2B ▼ |
| Q2-2025 | $13.41B | $9.32B | $-19.07B | $16.15B | $6.37B | $1.41B |
CEO
Erez Israeli
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-11-05 | Forward | 5:1 |
| 2006-09-07 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 56
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V.
Shares:13.08M
Value:$174.02M
BLACKROCK, INC.
Shares:11.16M
Value:$148.43M
ROYAL BANK OF CANADA
Shares:10.16M
Value:$135.16M
Summary
Showing Top 3 of 306